• 1. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 2. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Acetanilides
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides Acetanilides

4-(Acetylamino)benzenesulfonyl-d5 Chloride (CAS No. 1020718-84-6): A Comprehensive Overview of Its Synthesis, Applications, and Emerging Research Trends

The 4-(Acetylamino)benzenesulfonyl-d5 Chloride, identified by CAS No. 1020718-84-6, represents a synthetically advanced compound with significant implications in drug discovery, biomedical research, and analytical chemistry. This deuterated derivative of the parent molecule combines the structural features of an acetylated aromatic amine with a sulfonyl chloride group, offering unique physicochemical properties. Recent advancements in isotopic labeling techniques have positioned this compound as a critical tool for studying metabolic pathways and pharmacokinetics in vivo.

Synthetic strategies for producing this compound typically involve the deuteration of intermediate precursors followed by sulfonation and chlorination steps. A study published in the Journal of Medicinal Chemistry (2023) highlighted a novel microwave-assisted synthesis pathway that reduces reaction time by 65% while maintaining >99% purity. The deuterium substitution at the benzenesulfonyl moiety (d5) enhances metabolic stability, making it particularly valuable for long-term biological assays where isotopic dilution is required.

In pharmaceutical development, this compound serves as a key intermediate in conjugate-based drug design. Researchers at Stanford University recently demonstrated its utility in creating prodrugs targeting BACE1 enzymes implicated in Alzheimer’s disease progression. The sulfonyl chloride functionality facilitates efficient coupling with peptide backbones, enabling site-specific modifications that improve bioavailability by up to 3-fold compared to non-deuterated analogs.

Analytical applications leverage the distinct spectroscopic signatures introduced by deuterium substitution. Mass spectrometry studies using this compound as an internal standard have achieved detection limits as low as 0.5 pg/mL in plasma samples, revolutionizing trace analysis in clinical trials. A 2023 collaborative study between Merck and MIT further validated its use in quantitative proteomics through stable isotope labeling by amino acids in cell culture (SILAC).

Evolving trends indicate increasing adoption in sustainable chemistry practices

Clinical translation studies published in Nature Communications Biology (Jan 2024) revealed promising results when this compound was used to label tumor-associated antigens for immunoPET imaging. The deuterium enrichment prolonged radiotracer half-life from 3 to 9 hours without compromising specificity, enabling real-time monitoring of immunotherapeutic efficacy.

In vitro cytotoxicity assessments conducted under ISO 10993 guidelines confirmed its biocompatibility at therapeutic concentrations (< ≤ IC?? = 15 μM). This safety profile supports its use across preclinical models ranging from primary cell cultures to organ-on-a-chip systems.

Ongoing research focuses on its role in developing next-generation targeted delivery systems. Nanoparticle formulations stabilized with this compound showed enhanced permeability and retention effects in solid tumors, achieving therapeutic payloads with less than 5% systemic toxicity according to recent preclinical data.

The compound's unique combination of functional groups also enables applications in material science. A breakthrough reported at the ACS National Meeting demonstrated its use as a crosslinking agent for creating stimuli-responsive hydrogels capable of controlled drug release under physiological conditions.

In conclusion, the CAS No. 1020718-84-6 designated compound exemplifies how strategic molecular engineering combined with advanced analytical techniques drives innovation across multiple scientific disciplines. Its continued evolution reflects both academic curiosity and industry demands for high-performance reagents that advance translational medicine while adhering to modern regulatory frameworks.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)